Bill Corl of Omega Laboratories Joins Cannabix Technologies Board of Directors
VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce William (Bill) R. Corl has joined the board of directors of the Company. Mr. Corl is the Chief Executive Officer for Omega Laboratories, Inc., (“Omega”) one of the leading advanced specimen drug testing laboratories in the world. Omega and Cannabix have been working together since May 2024 under a strategic partnership and development agreement to advance commercialization of the Company’s Marijuana Breath Test (MBT) technology.
Mr. Corl has spent the last twenty-six years creating and managing technology solutions in the diagnostic testing, media and radiology industries. Mr. Corl has spent the last twenty plus years helping advance the drug screening industry, including rallying support for the regulatory acceptance of hair and oral fluid testing for drugs of abuse in Washington D.C. He was the chair of the Laboratory and Drug Panel Standards for the Global Oil and Gas Industry Drug Testing Guidelines in addition to being an advisor to the United Nations Office of Drugs and Crime for the 2014 version of Guidelines for Testing Drugs under International Control in Hair, Sweat and Oral Fluid.
Mr. Corl has a strong background in international technology management and marketing. This includes designing, building and launching technology solutions as well as managing international business operations. Mr. Corl holds a BBA and an MBA in International Management from Baldwin Wallace College. Mr. Corl’s directorship was ratified at the Company’s AGM on July 24th.
Omega Laboratories, based in Ohio, USA, is an international industry leader in forensic drugs of abuse testing for over twenty years. Omega has multiple internationally recognized certifications and accreditations for its world class facility and has extensive experience in novel technology for detection of drugs of abuse.
Cannabix and Omega are moving quickly to launch with select key clients and ramping up commercialization efforts for the Marijuana Breath Test (MBT). Omega has integrated breath testing using Cannabix Breath Cartridges into its suite of services and testing protocols. Furthermore, the parties are working together on marketing, distribution, support, high speed manufacturing and logistics for the MBT. Cannabix and Omega are dedicated to advancing the science of testing breath for recent marijuana usage.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to plans described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that patent applications are not awarded by regulatory authorities; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
